Last reviewed · How we verify
YH001
At a glance
| Generic name | YH001 |
|---|---|
| Sponsor | Tracon Pharmaceuticals Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess YH002 in Combination with YH001 in Subjects with Advanced Solid Tumors (PHASE1)
- A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors (PHASE1)
- YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma (PHASE1, PHASE2)
- A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors (PHASE1)
- A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC (PHASE2)
- A Study to Evaluate YH001 in Subjects With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YH001 CI brief — competitive landscape report
- YH001 updates RSS · CI watch RSS
- Tracon Pharmaceuticals Inc. portfolio CI